VNCE compared with PLX: revenue, margins and what each company keeps, and the suppliers and customers both name

VNCEVince Holding Corp.

Mkt capRevenueRevenue

PLXProtalix BioTherapeutics, Inc.

Mkt capRevenueRevenue

Compare

VNCEVince Holding Corp.

PLXProtalix BioTherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

VNCE1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−21.16%—

PLX

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±12.4%▲+7.82%×0.63

May 13 '26±17.0%▲+1.05%×0.06

= impliedVNCE realized, solidPLX realized, hatchedOne scale, both sides: full bar = 29%× = |realized| ÷ impliedSource: market data

Q1 FY26

±15.2%

▼−20.79%

×1.37

Q3 FY25±28.3%▼−9.81%×0.35

VNCEVince Holding Corp.

10.64▲+0.42%· post 10.66

Mkt cap$138.1MRevenue$82MQ2 FY26Revenue$300MFY25

PLXProtalix BioTherapeutics, Inc.

2.60▼−0.57%· post 2.60

ClosedOct 30 '26

Mkt cap$208.7MRevenue$20MQ2 FY26Revenue$53MFY25

Compare

ClosedOct 30 '26

VNCEVince Holding Corp.

PLXProtalix BioTherapeutics, Inc.

10.64▲+0.42%post 10.66

Price

2.60▼−0.57%post 2.60

$138.1M

Mkt cap

$208.7M

Q2 FY26$82M

Revenue

$20MQ2 FY26

FY25$300M

Revenue

$53MFY25

VNCE10.64▲+0.42%vsPLX2.60▼−0.57%ClosedOct 30 '26